Inhibikase Therapeutics, Inc. (IKT)
2.41
-0.02
(-0.82%)
USD |
NASDAQ |
Sep 09, 13:39
Inhibikase Therapeutics Enterprise Value : 161.82M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 161.82M |
| September 04, 2026 | 171.06M |
| September 03, 2026 | 173.70M |
| September 02, 2026 | 171.06M |
| September 01, 2026 | 155.22M |
| August 31, 2026 | 145.98M |
| August 28, 2026 | 159.18M |
| August 27, 2026 | 167.10M |
| August 26, 2026 | 169.74M |
| August 25, 2026 | 171.06M |
| August 24, 2026 | 171.06M |
| August 21, 2026 | 156.54M |
| August 20, 2026 | 151.26M |
| August 19, 2026 | 164.46M |
| August 18, 2026 | 157.86M |
| August 17, 2026 | 156.54M |
| August 14, 2026 | 159.18M |
| August 13, 2026 | 159.18M |
| August 12, 2026 | 157.86M |
| August 11, 2026 | 164.46M |
| August 10, 2026 | 165.78M |
| August 07, 2026 | 167.10M |
| August 06, 2026 | 159.18M |
| August 05, 2026 | 157.86M |
| August 04, 2026 | 163.14M |
| Date | Value |
|---|---|
| August 03, 2026 | 132.77M |
| July 31, 2026 | 128.81M |
| July 30, 2026 | 142.02M |
| July 29, 2026 | 132.77M |
| July 28, 2026 | 145.98M |
| July 27, 2026 | 151.26M |
| July 24, 2026 | 148.62M |
| July 23, 2026 | 148.62M |
| July 22, 2026 | 127.49M |
| July 21, 2026 | 135.41M |
| July 20, 2026 | 135.41M |
| July 17, 2026 | 119.57M |
| July 16, 2026 | 106.37M |
| July 15, 2026 | 112.97M |
| July 14, 2026 | 112.97M |
| July 13, 2026 | 99.77M |
| July 10, 2026 | 110.33M |
| July 09, 2026 | 110.33M |
| July 08, 2026 | 114.29M |
| July 07, 2026 | 111.65M |
| July 06, 2026 | 102.41M |
| July 02, 2026 | 103.73M |
| July 01, 2026 | 97.12M |
| June 30, 2026 | 109.01M |
| June 29, 2026 | 84.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.59M |
| Total Expenses (Quarterly) | 19.59M |
| EPS Diluted (Quarterly) | -0.1122 |
| Earnings Yield | -18.11% |
| Normalized Earnings Yield | -18.19 |